{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T18:33:31Z","timestamp":1791830011277,"version":"4.3.4"},"reference-count":45,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2015,2,11]],"date-time":"2015-02-11T00:00:00Z","timestamp":1423612800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Exp Pharma Physio"],"published-print":{"date-parts":[[2015,3]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>\n<jats:list>\n\n<jats:list-item><jats:p>A rapid method using liquid chromatography tandem mass spectrometry for the quantification of olanzapine (<jats:styled-content style=\"fixed-case\">OLZ<\/jats:styled-content>) in human plasma was developed and validated. Venlafaxine was used as the internal standard (<jats:styled-content style=\"fixed-case\">IS<\/jats:styled-content>), and the samples were extracted from 400\u2010<jats:italic>\u03bc<\/jats:italic>L human plasma with methyl <jats:italic>tert<\/jats:italic>\u2010butyl ether for liquid\u2013liquid extraction.<\/jats:p><\/jats:list-item>\n\n<jats:list-item><jats:p>Chromatography was performed using an <jats:styled-content style=\"fixed-case\">ACE<\/jats:styled-content> C18, 125\u00a0\u00d7\u00a04.6\u2010mm i.d., 5\u2010<jats:italic>\u03bc<\/jats:italic>m column. The mobile phase consisted of water with 0.1% formic acid for solvent A and acetonitrile with 0.1% formic acid for solvent B (50\u00a0:\u00a050 v\/v) in isocratic mode. The flow rate was 1.2\u00a0mL\/min. The retention times for <jats:styled-content style=\"fixed-case\">OLZ<\/jats:styled-content> and the <jats:styled-content style=\"fixed-case\">IS<\/jats:styled-content> were 0.78 and 1.04\u00a0min, respectively. Tandem mass spectrometry operating in positive electrospray ionization mode with multiple reaction monitoring was used to detect <jats:styled-content style=\"fixed-case\">OLZ<\/jats:styled-content> and the <jats:styled-content style=\"fixed-case\">IS<\/jats:styled-content> (<jats:italic>m\/z<\/jats:italic>: 313.1\u00a0&gt;\u00a0256.1 and 278.1\u00a0&gt;\u00a0260.2, respectively).<\/jats:p><\/jats:list-item>\n\n<jats:list-item><jats:p>No significant matrix effects were observed on <jats:styled-content style=\"fixed-case\">OLZ<\/jats:styled-content> and the <jats:styled-content style=\"fixed-case\">IS<\/jats:styled-content> retention times, and the mean recovery of <jats:styled-content style=\"fixed-case\">OLZ<\/jats:styled-content> was 90.08%. The assay was linear in the concentration range of 1\u201320\u00a0ng\/mL (<jats:italic>R<\/jats:italic><jats:sup>2<\/jats:sup>\u00a0=\u00a00.9976). The intra\u2010 and inter\u2010day precision were &lt;\u00a011.60% and the accuracy was &lt;\u00a01.66%.<\/jats:p><\/jats:list-item>\n\n<jats:list-item><jats:p>This validated method was successfully applied to a pharmacokinetic study in which 10\u2010mg <jats:styled-content style=\"fixed-case\">OLZ<\/jats:styled-content> tablets were administered to healthy volunteers and their plasma <jats:styled-content style=\"fixed-case\">OLZ<\/jats:styled-content> levels were monitored over time. The tests showed that the <jats:styled-content style=\"fixed-case\">OLZ<\/jats:styled-content> test and reference drug (Zyprexa<jats:sup>\u00ae<\/jats:sup>) were bioequivalent, as 90% of the confidence intervals were within the 80\u2013125% interval proposed by regulatory agencies.<\/jats:p><\/jats:list-item>\n<\/jats:list>\n<\/jats:p>","DOI":"10.1111\/1440-1681.12353","type":"journal-article","created":{"date-parts":[[2014,12,9]],"date-time":"2014-12-09T18:23:20Z","timestamp":1418149400000},"page":"305-313","source":"Crossref","is-referenced-by-count":13,"title":["The development and validation of a method for quantifying olanzapine in human plasma by liquid chromatography tandem mass spectrometry and its application in a pharmacokinetic study"],"prefix":"10.1111","volume":"42","author":[{"given":"Noely Camila Tavares","family":"Cavalcanti Bedor","sequence":"first","affiliation":[{"name":"Center of Cosmetic and Pharmaceutical Development Department of Pharmaceutical Science Federal University of Pernambuco Recife Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danilo C\u00e9sar","family":"Galindo Bedor","sequence":"additional","affiliation":[{"name":"Center of Cosmetic and Pharmaceutical Development Department of Pharmaceutical Science Federal University of Pernambuco Recife Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos Eduardo","family":"Miranda de Sousa","sequence":"additional","affiliation":[{"name":"Center of Cosmetic and Pharmaceutical Development Department of Pharmaceutical Science Federal University of Pernambuco Recife Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felipe","family":"Nunes Bonif\u00e1cio","sequence":"additional","affiliation":[{"name":"Center of Cosmetic and Pharmaceutical Development Department of Pharmaceutical Science Federal University of Pernambuco Recife Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"da Mota Castelo Branco","sequence":"additional","affiliation":[{"name":"Center of Cosmetic and Pharmaceutical Development Department of Pharmaceutical Science Federal University of Pernambuco Recife Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leila","family":"Bastos Leal","sequence":"additional","affiliation":[{"name":"Center of Cosmetic and Pharmaceutical Development Department of Pharmaceutical Science Federal University of Pernambuco Recife Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davi","family":"Pereira de Santana","sequence":"additional","affiliation":[{"name":"Center of Cosmetic and Pharmaceutical Development Department of Pharmaceutical Science Federal University of Pernambuco Recife Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2015,2,11]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2009.03.008"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199753020-00007"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/0893-133X(95)00069-P"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004850-199509000-00006"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200464230-00006"},{"key":"e_1_2_7_7_1","volume-title":"Psychopharmacology of Antipsychotics","author":"Stahl SM","year":"1999"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0378-4347(00)00438-2"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2006.01.040"},{"key":"e_1_2_7_10_1","unstructured":"Food and Drug Administration.Medication Guide: Zyprexa\u00ae(Olanzapine) Tablet and Zyprexa\u00aeZydis\u00ae(Olanzapine).2009. Available from:http:\/\/www.fda.gov\/downloads\/Drugs\/DrugSafety\/UCM134700.pdf(acessed 22 December 2014)."},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1097\/00007691-200102000-00010"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0378-4347(01)00240-7"},{"key":"e_1_2_7_13_1","first-page":"191","article-title":"Determination of olanzapine in plasma by high\u2010performance liquid chromatography using ultraviolet absorbance detection","volume":"773","author":"Dusci LJ","year":"2002","journal-title":"J. Chromatogr. B Biomed. Sci. Appl."},{"key":"e_1_2_7_14_1","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1093\/clinchem\/47.9.1719","article-title":"Integration of olanzapine determinations in a HPLC\u2010diode array detection system for routine psychotropic drug monitoring","volume":"47","author":"Llorca PM","year":"2001","journal-title":"Clin. Chem."},{"key":"e_1_2_7_15_1","first-page":"179","article-title":"High\u2010performance liquid chromatographic method with diode array detection to identify and quantify atypical antipsychotics and haloperidol in plasma after overdose","volume":"788","author":"Titier K","year":"2003","journal-title":"J. Chromatogr. B Biomed. Sci. Appl."},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0378-4347(99)00017-1"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1097\/00007691-199706000-00011"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0378-4347(00)00518-1"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-2004-815527"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/0378-4347(95)00061-M"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2007.02.006"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0378-4347(99)00287-X"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/rcm.718"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0378-4347(01)00548-5"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13369-012-0249-7"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2004.01.005"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2003.11.037"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/jms.440"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1093\/jat\/33.4.212"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2010.03.040"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1002\/bmc.1750"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.apsb.2012.02.009"},{"key":"e_1_2_7_33_1","unstructured":"US Department of Health and Human Services Food and Drug Administration (FDA) Center for Drug Evaluation and Research (CDER) Center for Veterinary Medicine (CVM).Guidance for Industry: Bioanalytical Method Validation.2001. Available from:http:\/\/www.fda.gov\/downloads\/Drugs\/Guidances\/ucm070107.pdf(accessed 22 December 2014)."},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0033-1341427"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0032-1323659"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.4172\/jbb.1000064"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.2174\/157341212801619351"},{"key":"e_1_2_7_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2013.10.033"},{"key":"e_1_2_7_39_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-2001-19184"},{"key":"e_1_2_7_40_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.11-2-126"},{"key":"e_1_2_7_41_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2710.2008.01011.x"},{"key":"e_1_2_7_42_1","doi-asserted-by":"publisher","DOI":"10.1021\/ac020361s"},{"key":"e_1_2_7_43_1","volume-title":"Design and Analysis of Bioavailability and Bioequivalence Studies","author":"Chow SC","year":"2000"},{"key":"e_1_2_7_44_1","unstructured":"Ag\u00eancia Nacional de Vigil\u00e2ncia Sanit\u00e1ria.Guia para provas de biodisponibilidade relativa\/bioequival\u00eancia de medicamentos.2006. Available from:http:\/\/www.in.gov.br\/visualiza\/index.jsp?data=24\/04\/2006&jornal=1&pagina=101&totalArquivos=128(accessed 3 May 2013)."},{"key":"e_1_2_7_45_1","unstructured":"Committee for Medicinal Products for Human Use.Guideline on the Investigation of Bioequivalence.European Medicines Agency.2010. Available from:http:\/\/www.emea.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2010\/01\/WC500070039.pdf(accessed 2 May 2013)."},{"key":"e_1_2_7_46_1","unstructured":"US Food and Drug Administration.Guidance for Industry: Statistical Approaches to Establishing Bioequivalence.2001. Available from:http:\/\/www.fda.gov\/downloads\/Drugs\/Guidances\/ucm070244.pdf(accessed 2 May 2013)."}],"container-title":["Clinical and Experimental Pharmacology and Physiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2F1440-1681.12353","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1440-1681.12353","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T23:36:21Z","timestamp":1696289781000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1440-1681.12353"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2,11]]},"references-count":45,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,3]]}},"alternative-id":["10.1111\/1440-1681.12353"],"URL":"https:\/\/doi.org\/10.1111\/1440-1681.12353","archive":["Portico"],"relation":{},"ISSN":["0305-1870","1440-1681"],"issn-type":[{"value":"0305-1870","type":"print"},{"value":"1440-1681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,2,11]]}}}